This review introduces a novel paradigm in cancer biology, focusing on the nuclear phosphoinositide (PIPn)-p53 signalosome and its crucial role in regulating cell motility. Traditionally associated with cytoplasmic and membrane-bound signaling, PIPns are now recognized for orchestrating nuclear events including the stabilization of p53 and activation of nuclear AKT. The review emphasizes the interplay between wild-type or mutant p53 and nuclear PIPn metabolism, opening new directions for therapeutic strategies targeting metastasis.

This study reveals that dynamin 1 (DNM1) promotes N-cadherin recycling through caveolae-mediated endocytosis, maintaining epithelial-to-mesenchymal transition (EMT) plasticity and driving ovarian cancer metastasis. DNM1 deficiency disrupts N-cadherin/Rab11 co-localization, while β-1,3-galactosyltransferase 1 (B3GALT1) inhibits this process. Clinically, elevated DNM1 expression correlates with poor prognosis in high-grade serous ovarian cancer and enhances nanoparticle uptake, providing a novel therapeutic target.

This review discusses the evolution, challenges, and innovations of antibody-drug conjugates (ADCs) in cancer treatment. It focuses on the importance of precise target selection and engineering to improve efficacy while minimizing off-target toxicities. Recent advances such as pH-dependent antibodies, dual-epitope targeting, and AI-guided profiling are highlighted as promising strategies to enhance safety and therapeutic impact.

Neuroblastoma, a cancer mainly affecting children, is often difficult to treat. A team led by Jan Dörr and Anton Henssen at the Experimental and Clinical Research Center report in “Cancer Discovery,” a potential reason treatment sometimes fails and a new strategy to combat particularly resistant tumors.

Researchers have documented their use of a new RNA sequencing technology to uncover molecular drivers of cellular differentiation that could lead to better regenerative therapies. In addition to being used in the lab, the technique, Rapid Precision Run-On Sequencing (rPRO-seq), has the potential to help doctors understand patients’ disease states and response to treatment in real time.

The emerging role of SETD2 in regulating immune cell function is shedding light on potential therapeutic strategies for a range of immune-related diseases. As a key methyltransferase, SETD2 facilitates the trimethylation of lysine 36 on histone H3 (H3K36me3), a modification crucial for maintaining genomic stability and regulating gene transcription. Recent discoveries indicate that SETD2 not only influences tumorigenesis but also plays a pivotal role in the development, differentiation, and function of immune cells.